Larimar Therapeutics (LRMR) EPS (Basic): 2013-2020
Historic EPS (Basic) for Larimar Therapeutics (LRMR) over the last 6 years, with Mar 2020 value amounting to -$0.10.
- Larimar Therapeutics' EPS (Basic) rose 71.43% to -$0.10 in Q1 2020 from the same period last year, while for Mar 2020 it was -$0.96, marking a year-over-year increase of 44.19%. This contributed to the annual value of -$1.22 for FY2019, which is 35.79% up from last year.
- Latest data reveals that Larimar Therapeutics reported EPS (Basic) of -$0.10 as of Q1 2020, which was up 47.37% from -$0.19 recorded in Q4 2019.
- In the past 5 years, Larimar Therapeutics' EPS (Basic) registered a high of -$0.10 during Q1 2020, and its lowest value of -$0.65 during Q1 2016.
- Its 3-year average for EPS (Basic) is -$0.36, with a median of -$0.35 in 2019.
- Its EPS (Basic) has fluctuated over the past 5 years, first declined by 26.32% in 2017, then skyrocketed by 71.43% in 2020.
- Quarterly analysis of 5 years shows Larimar Therapeutics' EPS (Basic) stood at -$0.38 in 2016, then decreased by 26.32% to -$0.48 in 2017, then climbed by 18.75% to -$0.39 in 2018, then skyrocketed by 51.28% to -$0.19 in 2019, then soared by 71.43% to -$0.10 in 2020.
- Its EPS (Basic) was -$0.10 in Q1 2020, compared to -$0.19 in Q4 2019 and -$0.35 in Q3 2019.